ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial-Reference-Cited by-同舟云学术

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Published:2023-11 Issue:4 Volume:2 Page:100140
ISSN:2772-8293
Container-title:Journal of Allergy and Clinical Immunology: Global
language:en
Short-container-title:Journal of Allergy and Clinical Immunology: Global

Author:

Giavina-Bianchi Pedro^ORCID,Cua Eric,Risso Karine,Mondain Véronique,Vissian Anaïs,Joie Cécile,Pouletty Philippe,Gineste Paul,Ehrlich Hartmut J.,Kalil Jorge

Publisher

Elsevier BV

Reference20 articles.

1. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status;Guo;Mil Med Res,2020

2. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020

3. Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing;Vautrin;Sci Rep,2019

4. Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases;Tazi;Drug Discov Today,2021

5. ABX464 (obefazimod) for moderate to severe active ulcerative colitis: a randomised, placebo controlled phase 2b induction trial and 48 week extension;Vermeire;Lancet Gastroenterol Hepatol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of microRNAs in Immune Regulation with Translational and Clinical Applications;International Journal of Molecular Sciences;2024-02-05